CMPS News

In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake (SNOW) took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two decades. Eight SPACs joined the week’s diverse group of IPOs. The year’s largest IPO to date, Snowflake (SNOW) priced above...read more

COMPASS Pathways, a British Phase 2 biotech developing a psilocybin-based therapy for depression, raised $128 million by offering 7.5 million ADSs at $17, above the range of $14 to $16. The company offered 0.8 million more ADSs than anticipated. At pricing, the company raised 27% more in proceeds than expected. COMPASS Pathways plans to list on the Nasdaq under the symbol...read more

COMPASS Pathways, a British Phase 2 biotech developing a psilocybin-based therapy for depression, announced terms for its IPO on Monday. The Cheshire, United Kingdom-based company plans to raise $101 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, COMPASS Pathways would command a fully diluted market value of $569...read more

COMPASS Pathways, a British Phase 2 biotech developing a psilocybin-based therapy for depression, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company is focusing on using its proprietary formulation of psilocybin, COMP360, in conjunction with psychological support as a way to help individuals who have treatment-resistant...read more